These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 25352267)

  • 1. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.
    Roland CL; Yang AD; Katz MH; Chatterjee D; Wang H; Lin H; Vauthey JN; Pisters PW; Varadhachary GR; Wolff RA; Crane CH; Lee JE; Fleming JB
    Ann Surg Oncol; 2015 Apr; 22(4):1168-75. PubMed ID: 25352267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiologic Occult Metastases in Pancreatic Cancer: Analysis of Risk Factors and Survival Outcomes in the Age of Contemporary Neoadjuvant Multi-agent Chemotherapy.
    Yee EJ; Torphy RJ; Thielen ON; Easwaran L; Franklin O; Sugawara T; Bartsch C; Garduno N; McCarter MM; Ahrendt SA; Schulick RD; Del Chiaro M
    Ann Surg Oncol; 2024 Sep; 31(9):6127-6137. PubMed ID: 38780693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resected pancreatic adenocarcinoma: An Asian institution's experience.
    Ng KYY; Chow EWX; Jiang B; Lim C; Goh BKP; Lee SY; Teo JY; Tan DMY; Cheow PC; Ooi LLPJ; Chow PKH; Lee JJX; Kam JH; Koh YX; Jeyaraj PR; Tan EK; Choo SP; Chan CY; Chung AYF; Tai D
    Cancer Rep (Hoboken); 2021 Oct; 4(5):e1393. PubMed ID: 33939335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma.
    Wang LM; Silva MA; D'Costa Z; Bockelmann R; Soonawalla Z; Liu S; O'Neill E; Mukherjee S; McKenna WG; Muschel R; Fokas E
    Oncotarget; 2016 Jan; 7(4):4183-94. PubMed ID: 26716653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer.
    Honselmann KC; Pergolini I; Castillo CF; Deshpande V; Ting D; Taylor MS; Bolm L; Qadan M; Wellner U; Sandini M; Bausch D; Warshaw AL; Lillemoe KD; Keck T; Ferrone CR
    Ann Surg; 2020 Aug; 272(2):357-365. PubMed ID: 32675550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nodal counts and lymph node ratio impact survival after distal pancreatectomy for pancreatic adenocarcinoma.
    Ashfaq A; Pockaj BA; Gray RJ; Halfdanarson TR; Wasif N
    J Gastrointest Surg; 2014 Nov; 18(11):1929-35. PubMed ID: 24916590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival.
    Lee SM; Katz MH; Liu L; Sundar M; Wang H; Varadhachary GR; Wolff RA; Lee JE; Maitra A; Fleming JB; Rashid A; Wang H
    Am J Surg Pathol; 2016 Dec; 40(12):1653-1660. PubMed ID: 27631521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Significance of Neoadjuvant Chemotherapy With Gemcitabine Plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma.
    Suzuki T; Mori S; Shimizu T; Tago K; Harada N; Park KH; Sakuraoka Y; Shiraki T; Iso Y; Aoki T; Kubota K
    In Vivo; 2019; 33(6):2027-2035. PubMed ID: 31662534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemotherapy is associated with improved disease-free survival in pancreatic cancer patients undergoing pancreaticoduodenectomy with vascular resection.
    Dillon DL; Park JY; Mederos MA; Seo YJ; King J; Hines J; Donahue T; Girgis MD
    J Surg Oncol; 2024 Jul; 130(1):72-82. PubMed ID: 38726668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Barriers to resection following neoadjuvant chemotherapy for resectable pancreatic adenocarcinoma: A national and local perspective.
    Fromer MW; Mouw TJ; Scoggins CR; Egger ME; Philips P; McMasters KM; Martin RCG
    J Surg Oncol; 2024 Aug; 130(2):284-292. PubMed ID: 38828742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative Chemotherapy.
    Swords DS; Francis SR; Lloyd S; Garrido-Laguna I; Mulvihill SJ; Gruhl JD; Christensen MC; Stoddard GJ; Firpo MA; Scaife CL
    J Gastrointest Surg; 2019 Jul; 23(7):1401-1413. PubMed ID: 30187332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripancreatic fat invasion is an independent predictor of poor outcome following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
    Jamieson NB; Foulis AK; Oien KA; Dickson EJ; Imrie CW; Carter R; McKay CJ
    J Gastrointest Surg; 2011 Mar; 15(3):512-24. PubMed ID: 21116727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant Chemotherapy With or Without Radiotherapy for Resected Pancreatic Cancer After Multiagent Neoadjuvant Chemotherapy.
    Franklin O; Sugawara T; Ross RB; Rodriguez Franco S; Colborn K; Karam S; Schulick RD; Del Chiaro M
    Ann Surg Oncol; 2024 Aug; 31(8):4966-4975. PubMed ID: 38789615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the mechanism of lymph node invasion affect survival in patients with pancreatic ductal adenocarcinoma?
    Konstantinidis IT; Deshpande V; Zheng H; Wargo JA; Fernandez-del Castillo C; Thayer SP; Androutsopoulos V; Lauwers GY; Warshaw AL; Ferrone CR
    J Gastrointest Surg; 2010 Feb; 14(2):261-7. PubMed ID: 19937477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic neoadjuvant chemotherapy in modern pancreatic cancer treatment: a systematic review and meta-analysis.
    Rangarajan K; Pucher PH; Armstrong T; Bateman A; Hamady Z
    Ann R Coll Surg Engl; 2019 Sep; 101(7):453-462. PubMed ID: 31304767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival.
    Tzeng CW; Tran Cao HS; Lee JE; Pisters PW; Varadhachary GR; Wolff RA; Abbruzzese JL; Crane CH; Evans DB; Wang H; Abbott DE; Vauthey JN; Aloia TA; Fleming JB; Katz MH
    J Gastrointest Surg; 2014 Jan; 18(1):16-24; discussion 24-5. PubMed ID: 24241967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poorly Differentiated Medullary Phenotype Predicts Poor Survival in Early Lymph Node-Negative Gastro-Esophageal Adenocarcinomas.
    Treese C; Sanchez P; Grabowski P; Berg E; Bläker H; Kruschewski M; Haase O; Hummel M; Daum S
    PLoS One; 2016; 11(12):e0168237. PubMed ID: 28030564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mode of spread in the early phase of lymphatic metastasis in pancreatic ductal adenocarcinoma: prognostic significance of nodal microinvolvement.
    Bogoevski D; Yekebas EF; Schurr P; Kaifi JT; Kutup A; Erbersdobler A; Pantel K; Izbicki JR
    Ann Surg; 2004 Dec; 240(6):993-1000; discussion 1000-1. PubMed ID: 15570205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Efficacy of Neoadjuvant Chemotherapy with Gemcitabine plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma Compared with Upfront Surgery.
    Kitano Y; Inoue Y; Takeda T; Oba A; Ono Y; Sato T; Ito H; Ozaka M; Sasaki T; Sasahira N; Baba H; Takahashi Y
    Ann Surg Oncol; 2023 Aug; 30(8):5093-5102. PubMed ID: 37140750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma.
    Wei D; Zaid MM; Katz MH; Prakash LR; Kim M; Tzeng CD; Lee JE; Agrawal A; Rashid A; Wang H; Varadhachary G; Wolff RA; Tamm EP; Bhosale PR; Maitra A; Koay EJ; Wang H
    Pancreatology; 2021 Jan; 21(1):200-207. PubMed ID: 33221151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.